Cover Image
市場調查報告書

全球流感市場

Global Influenza Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 317299
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
Back to Top
全球流感市場 Global Influenza Market 2014-2018
出版日期: 2014年10月22日 內容資訊: 英文 102 Pages
簡介

全球流感市場,預計2013年∼2018年的期間中,年複合成長率為8.10%。

本報告提供全球流感市場相關調查分析、市場規模與成長率、市場趨勢、推動市場要素與課題、市場機會驗證、主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 疾病概要

  • 簡介、分類
    • 季節性流感
    • 流行性流感
    • 人畜共通或變異型流感
  • 流感的季節
  • 地區分佈

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 市場區隔:流感病毒的各類型

  • 流感A型病毒
  • 流感B型病毒
  • 流感C型病毒

第9章 全球H1N1疫苗市場

  • 市場佔有率
  • 市場區隔
  • 市場規模與預測
  • 地區區分

第10章 市場區隔:各產品類型

第11章 全球流感治療藥市場

  • 市場區隔
  • 市場規模與預測
  • 已經過核准流感治療藥

第12章 全球流感疫苗市場

  • 市場區隔
  • 市場規模與預測
  • WHO的建議
  • 主要的已核准流感疫苗

第13章 地區區分

第14章 購買標準

第15章 市場成長因素

第16章 成長因素與其影響

第17章 市場課題

第18章 成長因素與課題的影響

第19章 市場趨勢

第20章 趨勢與其影響

第21章 業者情勢

  • 競爭情形
  • 市場佔有率分析
  • 其他卓越供應商

第22章 主要供應商分析

  • AstraZeneca
    • 主要資料
    • 產業概要
    • 產品區隔
    • 產業策略
    • 收益:各產業分類
    • 收益比較
    • 銷售額收益:各區域區隔
    • 主要的發展
    • SWOT分析
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Sanofi Pasteur

第23章 相關報告

圖表清單

目錄
Product Code: IRTNTR4394

About Influenza

Influenza is a contagious respiratory disease caused by influenza viruses. These viruses infect the nose, throat, and lungs causing mild to severe illness. The disease can be fatal in some cases. Elderly people, young children, and people with medical conditions including liver disorders, blood disorders, kidney disorders, chronic lung disease, asthma, and neurodevelopmental and neurological conditions are at a higher risk of getting infected. Influenza vaccines are administered for active immunization against influenza virus. This, in turn, confers protection against influenza disease. Vaccination of high-risk groups prevents unnecessary hospitalizations and premature deaths resulting due to influenza.

TechNavio's analysts forecast the Global Influenza market to grow at a CAGR of 8.10 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Influenza market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of various vaccines and drugs administered to prevent and treat human infection caused by influenza virus.

TechNavio's report, the Global Influenza Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Influenza market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • AstraZeneca
  • F. Hoffmann-La Roche
  • GlaxoSmithKline plc
  • Novartis
  • Sanofi Pasteur

Other Prominent Vendors

  • Abbott
  • Baxter International
  • bioCSL
  • Crucell
  • Mitsubishi Tanabe Pharma
  • Protein Sciences
  • Serum Institute of India
  • Sinovac Biotech
  • Zydus Cadila

Market Driver

  • Increased Awareness about Influenza
  • For a full, detailed list, view our report

Market Challenge

  • Antigenic Drift of Influenza Virus
  • For a full, detailed list, view our report

Market Trend

  • Emergence of Quadrivalent Vaccines for H1N1 Influenza
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Introduction and Classification
    • 06.1.1. Seasonal Influenza
    • 06.1.2. Pandemic influenza
    • 06.1.3. Zoonotic or variant influenza
  • 06.2. Influenza Season
  • 06.3. Geographical Distribution

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Type of Influenza Virus

    • 08.1.1. Influenza Type A Viruses
    • 08.1.2. Influenza Type B Viruses
    • 08.1.3. Influenza Type C Viruses

09. Global H1N1 Vaccines Market 2013-2018

  • 09.1. Market Share
  • 09.2. Market Segmentation
  • 09.3. Market Size and Forecast
  • 09.4. Geographical Segmentation

10. Market Segmentation by Product Type

11. Global Influenza Drugs Market

  • 11.1. Market Segmentation
    • 11.1.1. M2 Protein Inhibitors
    • 11.1.2. Neuraminidase Inhibitors
  • 11.2. Market Size and Forecast
  • 11.3. Key Approved Influenza Drugs
    • 11.3.1. In the US
    • 11.3.2. In the EU

12. Global Influenza Vaccines Market

  • 12.1. Market Segmentation
  • 12.2. Market Size and Forecast
  • 12.3. WHO Recommendation
  • 12.4. Key Approved Influenza Vaccines
    • 12.4.1. In the US
    • 12.4.2. In the EU

13. Geographical Segmentation

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2013
  • 21.3. Other Prominent Vendors

22. Key Vendor Analysis

  • 22.1. AstraZeneca
    • 22.1.1. Key Facts
    • 22.1.2. Business Description
    • 22.1.3. Business Segmentation
    • 22.1.4. Business Strategy
    • 22.1.5. Revenue by Business Segmentation
    • 22.1.6. Revenue Comparison 2011-2013
    • 22.1.7. Sales Revenue by Geographical Segmentation
    • 22.1.8. Key Developments
    • 22.1.9. SWOT Analysis
  • 22.2. F. Hoffmann-La Roche
    • 22.2.1. Key Facts
    • 22.2.2. Business Overview
    • 22.2.3. Business Segmentation
    • 22.2.4. Business Segmentation by Revenue 2012 and 2013
    • 22.2.5. Geographical Segmentation by Revenue
    • 22.2.6. Business Strategy
    • 22.2.7. Key Information
    • 22.2.8. SWOT Analysis
  • 22.3. GlaxoSmithKline
    • 22.3.1. Key Facts
    • 22.3.2. Business Overview
    • 22.3.3. Business Segmentation
    • 22.3.4. Business Segmentation by Revenue 2012 and 2013
    • 22.3.5. Sales by Geography
    • 22.3.6. Pipeline Products
    • 22.3.7. Business Strategy
    • 22.3.8. Key Information
    • 22.3.9. SWOT Analysis
  • 22.4. Novartis
    • 22.4.1. Key Facts
    • 22.4.2. Business Overview
    • 22.4.3. Business Segmentation by Revenue 2013
    • 22.4.4. Business Segmentation by Revenue 2012 and 2013
    • 22.4.5. Sales by Geography
    • 22.4.6. Business Strategy
    • 22.4.7. Key Developments
    • 22.4.8. SWOT Analysis
  • 22.5. Sanofi Pasteur
    • 22.5.1. Key Facts
    • 22.5.2. Business Overview
    • 22.5.3. Business Strategy
    • 22.5.4. Recent Developments
    • 22.5.5. SWOT Analysis

23. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Percentage of Influenza Positive Cases and Virus Subtypes for Week 32, 2014
  • Exhibit 3: Number of Specimens Tested Positive for Influenza by Subtype, Global
  • Exhibit 4: Number of Specimens Tested Positive for Influenza by Subtype in Northern Hemisphere
  • Exhibit 5: Number of Specimens Tested Positive for Influenza by Subtype in Southern Hemisphere
  • Exhibit 6: Global Influenza Market 2013-2018 (US$ million)
  • Exhibit 7: Global Influenza Market Segmentation by Type of Influenza Virus
  • Exhibit 8: Share of H1N1 Vaccines in Global Influenza Market 2013
  • Exhibit 9: Revenue Share of H1N1 Vaccines in Global Influenza Vaccines Market 2013
  • Exhibit 10: Global H1N1 Vaccines Market Segmentation by Route of Administration
  • Exhibit 11: Global H1N1 Vaccines Market 2013-2018 (US$ million)
  • Exhibit 12: Global H1N1 Vaccines Market by Geographical Segmentation 2013
  • Exhibit 13: Global Influenza Market Segmentation by Product Type
  • Exhibit 14: Global Influenza Market Segmentation by Product Type 2013
  • Exhibit 15: Global Influenza Market Segmentation by Product Type 2018
  • Exhibit 16: Global Influenza Market Segmentation by Application 2013-2018 (US$ million)
  • Exhibit 17: YoY Growth Rate of Global Influenza Market Segments 2013-2018
  • Exhibit 18: Global Influenza Market Segments 2013-2018
  • Exhibit 19: Global Influenza Drugs Market 2013-2018 (US$ million)
  • Exhibit 20: Global Influenza Vaccines Market Segmentation by Route of Administration
  • Exhibit 21: Global Influenza Vaccines Market 2013-2018 (US$ million)
  • Exhibit 22: Global Influenza Market by Geographical Segmentation 2013
  • Exhibit 23: Global Influenza Market Share Analysis 2013
  • Exhibit 24: Sanofi Pasteur's Influenza Vaccine Segmentation by Geography 2013
  • Exhibit 25: Sales of Tamiflu by Geography 2013
  • Exhibit 26: Sales of Fluarix/FluLaval by Geography 2013
  • Exhibit 27: Sales of FluMist/Fluenz by Geography 2013
  • Exhibit 28: AstraZeneca: Business Segmentation
  • Exhibit 29: AstraZeneca: Revenue by Business Segmentation 2013
  • Exhibit 30: AstraZeneca: Revenue by Business Segmentation 2011-2013 (US$ billion)
  • Exhibit 31: AstraZeneca: Sales Revenue by Geographical Segmentation 2013
  • Exhibit 32: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
  • Exhibit 33: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 34: F. Hoffmann-La Roche: Revenue of Pharmaceuticals Division by Geography 2013
  • Exhibit 35: F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geography 2013
  • Exhibit 36: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 37: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 38: GlaxoSmithKline: Sales by Geography 2013
  • Exhibit 39: GlaxoSmithKline: Pipeline Products 2013
  • Exhibit 40: Novartis AG: Business Segmentation by Revenue 2013
  • Exhibit 41: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 42: Novartis AG: Sales by Geography 2013
Back to Top